Melanoma

Introgen Awarded National Cancer Institute Grant To Evaluate INGN 241

Published in Gene Therapy Weekly, February 14th, 2002

Introgen Therapeutics, Inc., (INGN) has been awarded a $492,600 Small Business Technology Transfer (STTR) grant from the U.S. National Cancer Institute, to fund collaborative research with Elizabeth Grimm, PhD, professor in the department of bioimmunotherapy and codirector of the melanoma program at The University of Texas M.D. Anderson Cancer Center, and principal investigator of the study.

The research collaboration will help advance preclinical development of INGN 241, (adenoviral-mda7), Introgen's novel gene-based drug designed to kill cancer cells without harming normal cells.

The grant, titled "Gene Therapy for Human Malignant Melanoma," is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-02-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry